RxDoctor Payments Data

Gonzalo Pares, MD

Neurology · Spartanburg, SCNPI 1982809042

Payments from drug & device makers

$9,510in general payments, 2019–2025

Across 251 payments — averaging $37.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Livanova USA, Inc.$2K
  • AbbVie$722
  • EMD Serono, Inc.$326
  • Sunovion Pharmaceuticals Inc.$275
  • UCB, Inc.$267
  • plus $2K from 34 others

What the payments were for

  • Speaking & faculty fees$120%
  • Travel & lodging$1,62717%
  • Food & beverage$5,12154%
  • Education$170%
  • Gifts$2,73329%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,510 in reported general payments places this provider in the 70th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$101,597
Medicare patients
264
Services billed
1,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)11$84,604
AptiomEslicarbazepine Acetate17$24,023
FycompaPerampanel11$13,883
Levetiracetam224$6,932
Divalproex Sodium ErDivalproex Sodium35$4,359
Gabapentin150$3,506
Pregabalin174$3,460
Lacosamide51$3,299
Lamotrigine139$2,638
Oxcarbazepine57$2,475
Duloxetine Hcl79$2,110
Memantine Hcl62$1,935
ClopidogrelClopidogrel Bisulfate106$1,501
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen124$1,479
Donepezil Hcl86$1,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$275$24,02317 claims
Eisai Inc.Fycompa$160$13,88311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 270 neurology providers in South Carolina.

Other neurology in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →